Assenagon Asset Management S.A. Cytom X Therapeutics, Inc. Transaction History
Assenagon Asset Management S.A.
- $54.8 Billion
- Q1 2025
A detailed history of Assenagon Asset Management S.A. transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Assenagon Asset Management S.A. holds 711,454 shares of CTMX stock, worth $668,766. This represents 0.0% of its overall portfolio holdings.
Number of Shares
711,454
Previous 599,850
18.61%
Holding current value
$668,766
Previous $617,000
26.26%
% of portfolio
0.0%
Previous 0.0%
Shares
22 transactions
Others Institutions Holding CTMX
# of Institutions
70Shares Held
46.7MCall Options Held
3.7KPut Options Held
4.7K-
Tang Capital Management LLC San Diego, CA7.31MShares$6.87 Million0.57% of portfolio
-
Bvf Inc San Francisco, CA5.23MShares$4.91 Million0.2% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.16MShares$4.85 Million0.0% of portfolio
-
Prosight Management, LP Dallas, TX3.91MShares$3.67 Million1.19% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.22MShares$3.03 Million0.0% of portfolio
About CytomX Therapeutics, Inc.
- Ticker CTMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,950,200
- Market Cap $62M
- Description
- CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...